The IND application of GT0918 (Proxalutamide tablets) for breast cancer indications has been submitted to and accepted by NMPA in China

(Summary description)

The IND application of GT0918 (Proxalutamide tablets) for breast cancer indications has been submitted to and accepted by NMPA in China

(Summary description)

Information
The phase II clinical trials of GT0918 (Proxalutamide tablets) project for prostate cancer indications have been launched in China
Suzhou Kintor has signed a MAH cooperation agreement with TOT BIOPHARM on GT0918 (Proxalutamide tablets) project

Scan the QR code to read on your phone

Previous: GT0918 (Proxalutamide tablets) project has been awarded as the National Special Project for "Significant Novel Drugs Development" during the 13th Five-Year Plan period
Next: The GT0918 (Proxalutamide tablets) project has obtained clinical trials permission for prostate cancer indications in China and the United States, and phase I clinical trials have been launched in China
Previous: GT0918 (Proxalutamide tablets) project has been awarded as the National Special Project for "Significant Novel Drugs Development" during the 13th Five-Year Plan period
Next: The GT0918 (Proxalutamide tablets) project has obtained clinical trials permission for prostate cancer indications in China and the United States, and phase I clinical trials have been launched in China